Since the first patient received allogeneic hematopoietic cell transplantation (allo-HCT) to treat thalassemia, an inherited blood disorder affecting hemoglobin, in 1982, the therapy has rapidly grown ...
Hosted on MSN
What To Know About Graft vs. Host Disease (GVHD)
Graft vs. host disease (GVHD) can occur after a stem cell transplant from a donor. Transplants replace unhealthy cells with healthy blood-forming cells, which can treat some cancers. GVHD happens when ...
Findings from the phase 2 AGAVE-201 study showed an ORR of 75%, with all responders having a partial response. The Food and Drug Administration (FDA) has approved Niktimvo (axatilimab-csfr) for the ...
Sergio A. Giralt, MD, discusses how the pathophysiology of chronic graft-vs-host disease involves complex immune dysregulation, with CSF1R playing a crucial role in driving the differentiation of ...
As a hematologist and physician-scientist who specializes in bone marrow transplantation, Dr. Albert Yeh describes the “holy grail” of transplantation biology that has yet to be answered: “how do you ...
An allogeneic hematopoietic stem cell transplantation that triggers graft-vs.-host-disease (GVHD) involves T cells that do not come from the patient's bloodstream, but rather from the local progenitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback